Clinical Trial Update: Genetically Modified Haploidentical Natural Killer Cell Infusions for B-Lineage Acute Lymphoblastic Leukemia [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating genetically modified haploidentical natural killer cell infusions for B-lineage acute lymphoblastic leukemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• B-cell Acute Lymphoblastic Leukemia

Drugs mentioned

• Genetically Modified Haploidentical Natural Killer Cell Infusion (genetically modified haploidentical natural killer cells)

Snippet

Sponsor: St. Jude Children's Research Hospital | Conditions: Lymphoblastic Leukemia, Acute | Phase 1 | Status: COMPLETED